e-learning
resources
Munich 2006
Tuesday 05.09.2006
Hospital-acquired pneumonia: from inflammation to treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria
E. Mouloudi, K. Katsanoulas, M. Tsivitanidou, P. Pappas, A. Efthimiou, M. Asimaki, N. Sounidakis, N. Gritsi-Gerogianni (Thessaloniki, Greece)
Source:
Annual Congress 2006 - Hospital-acquired pneumonia: from inflammation to treatment
Session:
Hospital-acquired pneumonia: from inflammation to treatment
Session type:
Poster Discussion
Number:
4503
Disease area:
Respiratory critical care, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Mouloudi, K. Katsanoulas, M. Tsivitanidou, P. Pappas, A. Efthimiou, M. Asimaki, N. Sounidakis, N. Gritsi-Gerogianni (Thessaloniki, Greece). Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria. Eur Respir J 2006; 28: Suppl. 50, 4503
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Source: Eur Respir J 2007; 30: 307-313
Year: 2007
Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients
Source: Eur Respir J 2003; 22: 77S-83S
Year: 2003
Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobactor baumannii infection
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007
Ventilator-associated pneumonia (VAP) pathogenic microorganisms eradication and persistence during antimicrobial therapy
Source: Annual Congress 2013 –Recent developments in pneumonia
Year: 2013
Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
New antibiotics for VAP
Source: Eur Respir Mon 2011; 53: 48-53
Year: 2011
Nebulised colistin for ventilator-associated pneumonia prevention
Source: Eur Respir J 2015; 46: 1732-1739
Year: 2015
VAP: approach to therapy
Source: Eur Respir Mon 2011; 53: 36-47
Year: 2011
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia
Source: Eur Respir J 2007; 29: 548-560
Year: 2007
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006
Multidrug-resistant bacteria in community-acquired pneumonia
Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice
Year: 2017
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
Aerosolised treatment for VAP
Source: Eur Respir Mon 2011; 53: 54-65
Year: 2011
Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients
Source: Eur Respir J 2016; 47: 1060-1061
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept